Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVRO
CUSIPN/A
Phone650-251-0005
Debt
Debt-to-Equity Ratio0.61
Current Ratio8.06
Quick Ratio6.29
Price-To-Earnings
Trailing P/E Ratio-49.85
Forward P/E Ratio-42.23
P/E GrowthN/A
Sales & Book Value
Annual Sales$326.67 million
Price / Sales5.65
Cash FlowN/A
Price / CashN/A
Book Value$8.41 per share
Price / Book7.28
Profitability
EPS (Most Recent Fiscal Year)($1.25)
Net Income$-36,650,000.00
Net Margins-10.68%
Return on Equity-15.84%
Return on Assets-8.70%
Miscellaneous
Employees676
Outstanding Shares30,120,000
Market Cap$1.93 billion
Nevro (NYSE:NVRO) Frequently Asked Questions
What is Nevro's stock symbol?
Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro's earnings last quarter?
Nevro Corp (NYSE:NVRO) announced its quarterly earnings data on Thursday, August, 2nd. The medical equipment provider reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.04. The medical equipment provider had revenue of $96.10 million for the quarter, compared to analysts' expectations of $96.10 million. Nevro had a negative net margin of 10.68% and a negative return on equity of 15.84%. The business's revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.40) earnings per share. View Nevro's Earnings History.
When is Nevro's next earnings date?
What price target have analysts set for NVRO?
10 analysts have issued 12 month target prices for Nevro's stock. Their forecasts range from $62.00 to $105.00. On average, they anticipate Nevro's share price to reach $81.8889 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price. View Analyst Price Targets for Nevro.
What is the consensus analysts' recommendation for Nevro?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nevro.
Who are some of Nevro's key competitors?
Some companies that are related to Nevro include Hill-Rom (HRC), ICU Medical (ICUI), Integra Lifesciences (IART), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Tandem Diabetes Care (TNDM), Glaukos (GKOS) and Mazor Robotics (MZOR).
Who are Nevro's key executives?
Nevro's management team includes the folowing people:
- Mr. Rami Elghandour, Pres, CEO & Director (Age 39)
- Mr. Andrew H. Galligan, Chief Financial Officer (Age 62)
- Mr. Patrick Schmitz, VP of Operations (Age 58)
- Mr. Doug Alleavitch, VP of Quality (Age 57)
- Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 44)
Has Nevro been receiving favorable news coverage?
Media coverage about NVRO stock has been trending somewhat positive on Friday, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nevro earned a daily sentiment score of 0.18 on Accern's scale. They also gave news stories about the medical equipment provider an impact score of 46.32 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Nevro.
Who are Nevro's major shareholders?
Nevro's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.78%), Janus Henderson Group PLC (6.26%), Jennison Associates LLC (5.64%), Wells Fargo & Company MN (4.56%), Zevenbergen Capital Investments LLC (2.22%) and Artisan Partners Limited Partnership (1.98%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.
Which major investors are selling Nevro stock?
NVRO stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Point72 Asset Management L.P., Janus Henderson Group PLC, First Light Asset Management LLC, Kornitzer Capital Management Inc. KS, Russell Investments Group Ltd., Oak Ridge Investments LLC and Sivik Global Healthcare LLC. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Michael F Demane and Wilfred E Jaeger. View Insider Buying and Selling for Nevro.
Which major investors are buying Nevro stock?
NVRO stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Jennison Associates LLC, BlackRock Inc., FMR LLC, Zevenbergen Capital Investments LLC, Canada Pension Plan Investment Board, State of Wisconsin Investment Board and Waddell & Reed Financial Inc.. View Insider Buying and Selling for Nevro.
How do I buy shares of Nevro?
Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nevro's stock price today?
One share of NVRO stock can currently be purchased for approximately $61.46.
How big of a company is Nevro?
Nevro has a market capitalization of $1.93 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe.
How can I contact Nevro?
Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]
MarketBeat Community Rating for Nevro (NYSE NVRO)
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
